Dual GIP and GLP-1 mechanism

Two receptors, one metabolic reset

With the structure understood, this unit follows the signal inward. The US label states what the drug does: it stimulates insulin secretion in a glucose-dependent manner, reduces glucagon secretion, delays gastric emptying and decreases calorie intake, and both receptors it targets are present in brain regions that regulate appetite. It also reports increased insulin sensitivity in a clamp study in type 2 diabetes after 28 weeks of treatment.

You will see where in the body it acts, how the beta-cell responds, and why combining two incretin signals does more than either alone.